- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01670786
Safety Profile of Iodopovidone as an Agent for Pleurodesis in Malignant Pleural Effusion
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Background: Chemical pleurodesis is the treatment of choice in most cases of malignant pleural effusion. The literature mentions a variety of chemicals which may be used for this purpose, each with its own advantages and disadvantages. The iodopovidone has been recently studied due to the existence of some side effects of other agents. Nevertheless, there are still some questions in the literature regarding its safety and possible adverse effects. Because of these questions, we propose the development of a study to ensure the safety and efficacy of iodopovidone as a pleurodesis sclerosing agent.
Objective: The main purpose of this study is to evaluate the safety of pleurodesis for malignant pleural effusion using iodopovidone as a sclerosing agent in different doses. The secondary objectives are to determine clinical efficacy and quality of life of the patients after realization of the proposed procedure.
Methods: There will be a randomized clinical trial, covering patients diagnosed with malignant pleural effusion at Hospital Aristides Maltez - Bahia League Against Cancer. The research was revised and approved by the Ethics in Research of the Heart Institute, Hospital das Clínicas - FMUSP and of the Hospital Aristides Maltez - Bahia League Against Cancer. The free and informed consent was evaluated by the same authority pursuant and the study group included only those who agree to participate and signed an approved. There included patients with malignant pleural effusion diagnosis. Main exclusion criteria were iodine allergia, renal failure, thyroid disease, refusal to sign the informed consent and patients unable to respond the quality of life questionnaire. After inclusion, patients were randomized and assigned to two groups according to the iodopovidone concentration solution: 1% or 2%. All procedures were performed by infusion of the solution through a chest tube previously placed.The data analysis involved clinical measures and complementary exams trying to evaluate all organ systems and sorting through possible adverse effects, classifying those as CTCAEV. Clinical measures involved MRC dyspnea schedule, analogic visual pain schedule, visual acuity test, measurement of pulse oximetry, heart rate, blood pressure and temperature. Complementary exams were chest x-ray, electrocardiogram and laboratory tests. Such measures were performed in the preoperative, immediate postoperative, second, fourth, eleventh and thirty days postoperative. Quality of life questionnaires was applied before and on thirty days postoperative as well. After that, randomized groups were compared.
Study Type
Enrollment (Actual)
Phase
- Phase 4
Contacts and Locations
Study Locations
-
-
BA
-
Salvador, BA, Brazil, 40285-001
- Hospital Aristides Maltez
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- malignant pleural effusion
- Recurrent pleural effusion
- Complete lung expansion (> 80%) after puncture emptying confirmed by chest radiography.
- Karnofsky index > 40.
- Agreed to participate in the study and sign an Informed Consent
Exclusion Criteria:
- Thrombocytopenia or coagulation disorders
- Patients with impaired renal function
- Pleural or active systemic infection
- Massive neoplastic infiltration of the skin
- Inability to understand the quality of life questionnaire
- Previous pleural procedures
- Allergy to iodine
- Thyroid disorders
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: DOUBLE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: Iodopovidone 1%
The patients enrolled in this arm were submitted to pleurodesis with iodopovidone 1% administration into pleural cavity.
|
Comparison of two dosages of iodopovidone as an agent for pleurodesis in malignant pleural effusion
|
EXPERIMENTAL: Iodopovidone 2%
The patients enrolled in this arm were submitted to pleurodesis with iodopovidone 2% administration into pleural cavity.
|
Comparison of two dosages of iodopovidone as an agent for pleurodesis in malignant pleural effusion
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Safety of iodopovidone as an agent for pleurodesis
Time Frame: Until 30th day after surgical procedure
|
The safety was assessed by mean clinical measures as MRC dyspnea schedule, analogic visual pain schedule, visual acuity test, measurement of pulse oximetry, heart rate, blood pressure and temperature.
Complementary exams were chest x-ray, electrocardiogram and laboratory tests.
|
Until 30th day after surgical procedure
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Quality of life
Time Frame: Until 1 week before the procedure date and 1 month after it
|
Quality of life questionnaires were applied until 1 week before the procedure date and on thirty days postoperative as well.
|
Until 1 week before the procedure date and 1 month after it
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Efficacy of iodopovidone as an agent for pleurodesis
Time Frame: Procedure date and 2nd, 4th, 11st and 30th day after the surgical procedure
|
The efficacy assessment was based on need of additional pleural surgical procedures.
|
Procedure date and 2nd, 4th, 11st and 30th day after the surgical procedure
|
Collaborators and Investigators
Investigators
- Study Chair: Ricardo M Terra, MD, PhD, InCor Heart Institute
Study record dates
Study Major Dates
Study Start
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
Study Record Updates
Last Update Posted (ESTIMATE)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- GPPOT-02
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Pleural Effusion, Malignant
-
Sheng HuWuhan Binhui Biotechnology Co., Ltd.RecruitingMalignant Pleural Effusion | Malignant Peritoneal EffusionChina
-
Huazhong University of Science and TechnologyUnknownMalignant Ascites | Malignant Pleural Effusion,China
-
Clover Biopharmaceuticals AUS Pty LtdCompletedMalignant Pleural EffusionsAustralia
-
Singapore General HospitalCompletedMalignant Pleural EffusionsSingapore
-
Naestved HospitalTerminatedMalignant Pleural Effusion | Exudative Pleural EffusionDenmark
-
Johns Hopkins UniversityEnrolling by invitationMalignant Pleural EffusionsUnited States
-
Wuhan YZY Biopharma Co., Ltd.Not yet recruitingA Phase Ib/II Clinical Trial of M701 in the Treatment of Malignant Pleural Effusions Caused by NSCLCNSCLC Stage IV | Malignant Pleural EffusionsChina
-
M.D. Anderson Cancer CenterTerminatedAdvanced Cancers | Malignant Pleural EffusionsUnited States
-
Eastern Regional Medical CenterRecruitingLoculated or Non-draining Malignant Pleural EffusionsUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)RecruitingPleural NeoplasmUnited States
Clinical Trials on pleurodesis
-
Assistance Publique Hopitaux De MarseilleCompleted
-
Beijing Haidian HospitalPeking University People's HospitalUnknownPneumothorax | PleurodesisChina
-
Imam Abdulrahman Bin Faisal UniversityKing Fahad Specialist Hospital Dammam; Qatif Central Hospital; Johns Hopkins...RecruitingThoracic Surgical ProceduresSaudi Arabia
-
National Taiwan University HospitalUnknownPCL Pleurodesis
-
Guy's and St Thomas' NHS Foundation TrustBecton, Dickinson and CompanyUnknownPleural Effusion, MalignantUnited Kingdom
-
Assiut UniversityRecruitingThoracic Cancer | Malignant Pleural EffusionEgypt
-
National University Hospital, SingaporeUnknownPleural Effusion, MalignantSingapore
-
Heidelberg UniversityCompleted
-
University of PennsylvaniaTerminatedPleural Diseases | Pleural Effusion, Malignant | PleurodesisUnited States